BeOne presenta en la EHA 2026 resultados históricos de fase 3 en pacientes de 80 años o más con LLC que confirman el beneficio de BRUKINSA

Key Takeaway: BeOne presented historical Phase 3 results at EHA 2026 regarding the benefits of BRUKINSA in patients aged 80 and older with CLL. The findings contribute to the understanding of treatment efficacy in this demographic. Further details on the study's outcomes were not provided in the article.